Overview
Heavy chain deposition disease (HCDD) is a rare disorder characterized by the deposition of monoclonal heavy chains in various organs, often leading to organ dysfunction, particularly renal impairment 1.Diagnosis
Renal dysfunction is a common presenting feature 12.
Presence of monoclonal immunoglobulin protein in serum or urine, though not always initially detectable 2.
Histopathological confirmation through biopsy showing heavy chain deposition 1.
Imaging and organ-specific function tests to assess extent of organ involvement 1.Management
First-line treatments:
- Steroids 12
- Alkylating agents (e.g., cyclophosphamide) 12
Adjunctive treatments:
- Bortezomib for more rapid reduction of heavy chains in serum and urine 1
- Autologous stem cell transplantation considered for prolonged dialysis-free survival 1Special Populations
Renal dysfunction considerations: Toxicity from certain therapies may be heightened in patients with pre-existing kidney dysfunction 1.Key Recommendations
Initiate treatment with steroids and alkylating agents for managing symptoms and slowing disease progression (Evidence: Moderate 12).
Consider bortezomib for patients with significant heavy chain levels, given its efficacy in reducing these levels (Evidence: Weak 1).
Evaluate autologous stem cell transplantation in selected patients to potentially prolong dialysis independence, weighing risks carefully (Evidence: Expert opinion 1).References
1 Jimenez-Zepeda VH. Light chain deposition disease: novel biological insights and treatment advances. International journal of laboratory hematology 2012. link
2 Pérez-Suárez G, Raya JM, Alvarez A, Martín A, Alvarez-Arguelles H, Hernández-Garcia M et al.. Progressive renal failure as the first manifestation of monoclonal light-chain deposition disease with rapid multiple organ involvement. Clinical nephrology 2009. link